Skip to content
Viyash Scientific logo

Viyash Scientific

VIYASH NSE
₹228.46 +9.01 (+4.11%)
P/E
39.66
View as Markdown
MCP
Close 4 Nov 2026 ₹228.46 +12.02 +5.55% 1Y
Start ₹216.44

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
13.40%
Debt to Equity
0.17
EPS (TTM)
₹5.76
Book Value
₹63.79
Market Cap
—
P/E (TTM)
39.66
P/B
3.58
ROE
7.39%
Dividend Yield
0.23%
EBITDA
₹696 Cr
52W High
₹298.00
52W Low
₹178.13
Day Range
₹215.00 – ₹229.58
Volume
15,72,201

Peer Comparison

Healthcare › Pharmaceuticals

Viyash Scientific peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Viyash Scientific (this company)
₹228.4639.66₹9,922 Cr3.580.23%7.39%13.40%₹3,575 Cr₹267 Cr
Median 8 companies₹1,587.7039.24₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

Category scores

Quality
45
Weak
Returns, margins, earnings quality 22% weight
Valuation
60
Good
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
39
Weak
Solvency, leverage, coverage 9% weight
Momentum
33
Poor
Trend strength, vol-adjusted 12% weight
Ownership
34
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 3.54 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 3.80% over last 3 years.
  • Working capital days have increased from 71.6 days to 111 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish856
OscillatorsNeutral252
Moving AveragesStrong Bearish604

Key readings

RSI (14)
50.57
Neutral
MACD (12,26,9)
−5.60
Bullish
SMA (50)
241.38
Bearish
SMA (200)
233.84
Bearish

As of

Analyst Rating

Based on 3 analysts
BUY100%

3 of 3 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
3
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+18.89%
5Y+20.22%
3Y+34.01%
1Y+13.73%
TTM+52.93%

Net profit

Net profit growth by window
10YTurned to profit
5Y+16.69%
3YTurned to profit
1YTiny base
TTM+181.05%

Operating cash flow

Operating cash flow growth by window
10YZero base
5Y+22.94%
3Y+166.84%
1Y−6.38%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+9.85 pp
5Y+3.52 pp
3Y+18.25 pp
1Y+6.22 pp
TTM+6.88 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹684 Cr
Mar 2018₹848 Cr
Mar 2019₹1,039 Cr
Mar 2020₹1,179 Cr
Mar 2021₹1,362 Cr
Mar 2022₹1,413 Cr
Mar 2023₹1,421 Cr
Mar 2024₹1,370 Cr
Mar 2025₹3,007 Cr
Mar 2026₹3,420 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹16.00 Cr
Mar 2018₹431 Cr
Mar 2019₹57.00 Cr
Mar 2020₹82.00 Cr
Mar 2021₹104 Cr
Mar 2022₹45.00 Cr
Mar 2023−₹122 Cr
Mar 2024−₹30.00 Cr
Mar 2025₹16.00 Cr
Mar 2026₹225 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹181 Cr −3.2% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 9 Jul 2026
AI opinion · based on fundamentals
Risk high

Viyash Scientific Ltd is a healthcare company with a market cap of Rs 12,252 Cr trading at a PE of 52.7x. The company has delivered exceptional TTM sales growth of 120% and TTM profit growth of 816%, though its 3-year ROE of 6% remains below average for the sector.

Bull Case 7
  • TTM revenue growth of 120% signals a significant acceleration in business momentum compared to the 3-year CAGR of 34%
  • Compounded profit growth of 816% on a TTM basis demonstrates substantial operating leverage kicking in
  • 3-year compounded sales CAGR of 34% shows consistent top-line expansion over a meaningful period
  • ROE has improved from 6% (3-year average) to 11% in the last year, indicating improving capital efficiency
  • 10-year compounded profit CAGR of 28% reflects a long-term track record of earnings growth
  • Stock has delivered 46% CAGR over 1 year and 3 years, reflecting sustained investor confidence
  • Company is expected to deliver a good upcoming quarter based on available estimates
Bear Case 7
  • 3-year ROE of only 6% is well below what investors typically expect from a quality healthcare compounder
  • Working capital days have deteriorated sharply from 70.3 days to 111 days, signaling potential cash conversion issues
  • Price-to-book of 4.07x is elevated, meaning investors are paying a significant premium over net asset value
  • Despite reporting repeated profits, the company pays negligible dividends (yield of only 0.18%), retaining capital without delivering proportionate ROE
  • 5-year ROE average of just 4% suggests historically poor returns on retained earnings
  • 5-year compounded profit CAGR of only 15% contrasts starkly with TTM figures, raising questions about sustainability of recent profit surge
  • 5-year stock CAGR of 0% prior to the recent rally indicates prolonged periods of value destruction for long-term holders

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

111d ago

TL;DR: Viyash Scientific is positioning itself as a top 10 global animal health company by 2030 with board strengthening and a clear strategic roadmap. Key risks include a SEBI administrative warning on compliance gaps and potential supply overhang from Carlyle's possible 10% stake sale. Governance is tightening with new director appointments and incentive approvals. The trend is cautiously positive on strategy but near-term overhang from promoter selling and regulatory scrutiny warrants monitoring.

Headwinds 2
  • SEBI warning on SDD gaps Jul 8

    SEBI issued an administrative warning to Viyash Scientific for SDD maintenance gaps from June to October 2024, citing incomplete information in the digital database.

  • Carlyle may sell 10% stake Jun 22

    Promoter Carlyle (holding 61.3%) may offload up to 10% stake per CNBC TV18. No timeline or pricing disclosed, creating potential supply overhang.

Positives 2
  • Two new directors appointed Jun 29

    Viyash appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive Directors. Shareholders also approved a performance incentive for WTD Mr. Rajaram Narayanan.

  • Top 10 global animal health target Jun 25

    At Investor Day 2026, Viyash outlined its strategy to become a top 10 global animal health player by 2030, highlighting its integrated animal and human health platform.

Neutral 2
  • AGM set for August 11 Jul 15

    Viyash Scientific will hold its 41st AGM via video conference on August 11, 2026. Remote e-voting opens August 7.

  • Investor Day hosted June 25 Jun 17

    Viyash hosted its Investor Day 2026 on June 25 in Mumbai for analysts and institutional investors.

Quarterly Results

₹ Cr
VIYASH quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
333
346
329
361
390
369
774
402
792
850
858
920
946
Expenses
341
331
307
329
348
330
674
355
673
677
683
736
768
Operating Profit
−8
15
22
32
42
39
100
46
119
173
176
184
178
OPM %
−2.5%
4.4%
7%
9%
11%
11%
13%
12%
15%
20%
20%
20%
19%
Other Income
−23
10
7
−1
3
0
4
1.66
6
2.15
−27
16
8
Interest
10
13
13
12
16
14
21
15
20
13.51
17
15
13
Depreciation
14
15
15
16
16
17
58
16
56
59
59
60
62
PBT
−56
−3
1
3
12
8
24
16
48
102
73
125
112
Tax %
−38%
123%
−617%
52%
24%
20%
−71%
36%
24%
29%
34%
47%
29%
Net Profit
−35
−7
11
1
9
6
42
10
37
73
49
66
79
EPS (₹)
−1.4
−0.34
0.33
−0.04
0.26
0.1
1.78
0.37
1.27
2.18
0.88
1.19
1.51

Profit & Loss

₹ Cr
VIYASH profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
443
606
684
848
1,039
1,179
1,362
1,413
1,421
1,370
3,007
3,420
3,575
Expenses
425
550
641
765
914
1,009
1,150
1,303
1,409
1,308
2,620
2,768
2,864
Operating Profit
18
56
43
83
125
170
212
109
12
61
387
653
711
OPM %
4.2%
9%
6%
10%
12%
14%
16%
8%
0.8%
4.5%
13%
19%
20%
Other Income
48
14
9
436
9
10
0
11
−58
−6
−49
−1
3
Interest
43
38
28
33
33
36
24
16
36
48
86
69
61
Depreciation
32
46
40
41
42
51
51
52
56
62
239
234
240
PBT
−8
−14
−17
444
59
94
137
53
−138
−55
13
349
413
Tax %
40%
19%
−3%
3%
3%
13%
24%
15%
−11%
−46%
−20%
36%
—
Net Profit
−12
−16
−16
431
57
82
104
45
−122
−30
16
225
267
EPS (₹)
−0.7
−0.78
−0.57
17.3
1.97
2.81
3.84
1.65
−4.86
−1.44
0.93
4.06
5.76
Div. Payout %
0%
0%
0%
1%
10%
0%
13%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
VIYASH balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
30
48
49
49
49
50
50
50
50
50
50
87
Reserves
61
898
928
599
657
637
678
642
649
607
2,382
2,824
Borrowings
473
312
416
305
325
343
277
365
444
488
654
490
Other Liabilities
343
265
503
380
346
424
381
378
374
389
1,042
1,195
Total Liabilities
908
1,523
1,896
1,332
1,378
1,454
1,386
1,435
1,517
1,534
4,128
4,596
Fixed Assets
474
586
684
476
498
577
536
564
605
592
2,103
2,103
CWIP
39
24
33
18
23
13
31
12
55
16
43
70
Investments
59
428
428
239
180
171
83
38
0
4
0
0
Other Assets
336
485
751
599
677
693
737
821
856
922
1,981
2,422
Total Assets
908
1,523
1,896
1,332
1,378
1,454
1,386
1,435
1,517
1,534
4,128
4,596

Cash Flow

₹ Cr
VIYASH cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−24
0
−7
45
116
115
115
31
17
31
345
323
Investing
−157
−310
−116
7
−68
−72
10
−94
−65
−6
−448
−84
Financing
179
309
147
−57
−20
−43
−139
67
32
−1
87
−123
Net Cash Flow
−1
−2
24
−5
28
0
−14
4
−16
23
−16
115
Free Cash Flow
−137
−63
−82
0
92
75
70
−1
−58
19
258
225
CFO/OP
−143
−3
5
65
92
75
75
52
263
73
102
59

Ratios

VIYASH financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
95
116
136
111
98
99
93
85
88
89
98
112
Inventory Days
153
164
165
125
134
132
139
160
152
166
169
188
Days Payable
147
175
208
127
141
133
119
119
107
121
121
140
Cash Conversion Cycle
101
105
93
110
92
98
112
126
132
135
146
160
Working Capital Days
−111
65
−25
20
33
29
51
54
46
30
74
111
ROCE %
8%
2%
1%
40%
9%
12%
16%
6%
−3%
0%
8%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Viyash Scientific insights

70 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.24%
  • Public 26.74%
  • Others 13.12%
  • DIIs 8.30%
  • FIIs 2.60%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Viyash Scientific

What does Viyash Scientific Ltd do?
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical…
Where is Viyash Scientific Ltd (VIYASH) listed?
Viyash Scientific Ltd trades as VIYASH on the NSE and under code 512529 on the BSE.
Which sector does Viyash Scientific Ltd belong to?
Viyash Scientific Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Viyash Scientific Ltd?
Viyash Scientific Ltd trades at a PE ratio of 39.66 as of 4 Nov 2026, on earnings per share of ₹5.76, against a book value of ₹63.79 per share.
What is the 52-week high and low of Viyash Scientific Ltd?
Over the last 52 weeks Viyash Scientific Ltd has traded between ₹178.13 and ₹298 as of 4 Nov 2026.
Does Viyash Scientific Ltd pay dividends?
Viyash Scientific Ltd has a dividend yield of 0.23%.
What is the Return on Equity (ROE) of Viyash Scientific Ltd?
Viyash Scientific Ltd reported a return on equity of 7.39%. Its debt-to-equity ratio is 0.17.

Company Information

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

Website sequent.in
Listed 10 Mar 2016
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIYASH.md for Viyash Scientific Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month